Evidence map›Paper›PMID 21860342›Full record

Trial reportTherapeutic drug monitoring2011

MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.

Allan J Barnes, Karl B Scheidweiler, Erin A Kolbrich-Spargo, David A Gorelick, Robert S Goodwin, Marilyn A Huestis

Abstract readClinical Trial
In one paragraph

Trial report in Therapeutic drug monitoring, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Identifying methamphetamine exposure in children.Therapeutic drug monitoring · 2013
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Allan J BarnesChemistry and Drug Metabolism, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA.
Karl B Scheidweiler
Erin A Kolbrich-Spargo
David A Gorelick
Robert S Goodwin
Marilyn A Huestis
National Institutes of Health · USNational Institute on Drug Abuse · US

Funding

Detection Of Drugs Of Abuse In Alternative Biological Fluids And TissuesZIADA000412 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SCHEIDWEILER, KARL · 2009 to 2016
$3.9M
Neurobiology and Pharmacokinetics of Acute MDMA AdministrationZIADA000468 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HUESTIS, MARILYN A · 2009 to 2013
$1.9M
Neurobiology /Pharmacokinetics of Acute MDMA AdministratZ01DA000468 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI HUESTIS, MARILYN A · 2004 to 2008
$1.2M
Intramural NIH HHS Z01 DA000468Intramural NIH HHS ZIA DA000468
6 · The paper itself

Abstract

introductionThe use of 3,4-methylenedioxymethamphetamine (MDMA) is increasing, enhancing the need for its detection in clinical, workplace, pain management, and driving under the influence of drugs testing programs. Oral fluid is an important alternative matrix for drug testing, but little is known about MDMA detection windows in oral fluid.

aimsThe aim was to characterize MDMA and metabolite disposition in expectorated oral fluid after controlled MDMA administration.

methodsPlacebo, low (1.0 mg/kg), and high (1.6 mg/kg) oral MDMA doses were given double-blind in random order in separate sessions to 29 healthy adults with histories of MDMA use. One thousand two hundred eighty-six expectorated oral fluid specimens collected up to 7 days after dosing were analyzed for MDMA, 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), and 4-hydroxy-3-methoxyamphetamine (HMA) by gas chromatography mass spectrometry. The limits of quantification were 5 ng/mL for MDMA and MDA and 10 ng/mL for HMA and HMMA.

resultsMDMA was the primary analyte detected, with concentrations up to 12,000 ng/mL in 872 specimens (67.8%). MDA was quantified in 656 specimens (51.0%) at concentrations <403 ng/mL and was never present without concurrent MDMA. HMA and HMMA were not detected. Of the specimens, 59.8%, 58.6%, and 54.9% were found to be MDMA positive at the Talloires (20 ng/mL), Driving under the Influence of Drugs, Alcohol, and Medicines (25 ng/mL) and proposed US Substance Abuse and Mental Health Services Administration (50 ng/mL) confirmation cutoffs, respectively. MDMA was first observed in oral fluid 0.25-1.25 hours after dosing; MDA was initially detected at 0.5-1.75 hours. In general, the windows of detection for MDMA and MDA were 47 and 29 hours, respectively, although a few specimens were positive up to 71 and 47 hours.

conclusionsOral fluid monitoring efficiently detects single, recreational 70-150 mg of MDMA use for 1-2 days. These controlled administration data provide a scientific basis for interpreting MDMA oral fluid test results.

Indexed as

Administration, OralAdolescentAdultCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleN-Methyl-3,4-methylenedioxyamphetamineSalivaYoung AdultN-Methyl-3,4-methylenedioxyamphetamine

Identifiers

PMID21860342
PMCPMC3178664
OpenAlexW2087875473

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.